الفهرس Only 14 pages are availabe for public view
 |  | from | 239 |  |  |
| | | from | 239 | | |
Abstract
Over the last decade new diagnostic and therapeuticdevelopments have resulted in higher cure rate for patients withaggresive non-Hodgkin’s lymphoma. A more precise definition ofthe variables of prognostic significance has led to a more rationalstratification of patients into multiple risk categories for whichdifferent therapeutic stratigies are required.
In this study, we aim to explore the ability of the combineddetection of soluble 1L-2 receptor and interleukin-1 0 to predicttreatment failure in patients with aggressive non-Hodgkin’slymphoma.
Sixty avaluable patients with aggressive NI-ILs were admittedto the Medical Oncology and Hematology Unit, Internal MedicineDepartment Zagazig University Hospitals compared to ten healthyvolunteers as a control group (group IV).
Patients were subdivided into three groups according to theirresponse to treatment there were :
Group I : 20 patients showing complete remission after treatment.Group II : 20 patients showing partial remission after treatment.Group III : 20 patients showing no respone after treatment.
All subjects were subjected to history and clinicalexamination routine laboratory investigation and specialinvestigation, including ESR, serum LDH, serum 1L-10 and serumSIL-2R before and after treatment.